{"id":1149,"date":"2014-09-01T12:04:00","date_gmt":"2014-09-01T10:04:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2014\/leserbrief-neue-orale-antikoagulanzien-oder-vitamin-k-antagonisten"},"modified":"2014-09-01T12:04:00","modified_gmt":"2014-09-01T10:04:00","slug":"leserbrief-neue-orale-antikoagulanzien-oder-vitamin-k-antagonisten","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2014\/leserbrief-neue-orale-antikoagulanzien-oder-vitamin-k-antagonisten","title":{"rendered":"Leserbrief: Neue orale Antikoagulanzien oder Vitamin-K-Antagonisten?"},"content":{"rendered":"<p>Prof. Dr. E.F. aus P. schreibt (stark gek\u00fcrzt): >> Die Ergebnisse der Metaanalyse von C.T. Ruff et al. (1) zur Verordnung der neuen oralen Antikoagulanzien (NOAK) bei Vorhofflimmern werden in Tab. 3 Ihres Artikels (2) hervorragend in die Praxis \u00fcbersetzt. Daneben sollte aber auch die 2012 publizierte Metaanalyse von C.S. Miller et al. (3) ber\u00fccksichtigt [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Prof. Dr. E.F. aus P. schreibt (stark gek\u00fcrzt): >> Die Ergebnisse der Metaanalyse von C.T. Ruff et al. (1) zur Verordnung der neuen oralen Antikoagulanzien (NOAK) bei Vorhofflimmern werden in Tab. 3 Ihres Artikels (2) hervorragend in die Praxis \u00fcbersetzt. Daneben sollte aber auch die 2012 publizierte Metaanalyse von C.S. Miller et al. (3) ber\u00fccksichtigt [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[185,137,1322,184,2305,1314,1312,2068,1328,1327,138,2304,54,51,181,136],"class_list":["post-1149","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-absolute-arrhythmie","tag-antikoagulanzien","tag-apixaban","tag-arrhythmien","tag-dabigatran","tag-direkte-orale-antikoagulanzien","tag-doak","tag-edoxaban","tag-neue-orale-antikoagulanzien","tag-noak","tag-phenprocoumon","tag-rivaroxaban","tag-thromboembolie","tag-thrombose","tag-vorhofflimmern","tag-warfarin"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1149","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1149"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1149\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1149"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1149"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1149"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}